Mount Sinai has the largest Sarcoidosis Service in the world and is one of only two institutions in the country participating in the trial; the other is the University of Cincinnati. Mount Sinai is a National Institutes of Health Center of Excellence for research in sarcoidosis.
"The current standard treatment for chronic pulmonary sarcoidosis is corticosteroids," said Adam Morgenthau, MD, principal investigator of the study and Director of the Sarcoidosis Clinic and the Alvin S. Teirstein Sarcoidosis Support Group at Mount Sinai. "Many patients don't respond to these drugs and those who do often develop long-term complications. We are hopeful this study will lead to new treatments to improve lung function and quality of life."
Sarcoidosis is a rare inflammatory disease that can affect any organ but most commonly involves the lungs. Patients with pulmonary sarcoidosis typically exhibit symptoms of shortness of breath, cough and/or wheeze. It affects men and women of all ages and races worldwide. However, it occurs mostly in people ages 20 to 40, African Americans, especially women, and people of Asian, German, Irish, Puerto Rican and Scandinavian origin, according to the National Institutes of Health.
The randomized placebo Phase II clinical trial at Mount Sinai for patients with sarcoidosis is designed to assess the safety, tolerability and efficacy of an antibody directed against macrophage colony-stimulating factor (m-CSF), a protein associated with the development of sarcoidosis. During a Phase I clinical trial for patients with rheumatoid arthritis (RA), the antibody was well tolerated in healthy people as well as patients with RA.
"This study has both clinical and basic science applications," said Dr. Morgenthau. "In addition to determining whether patients' symptoms improve with this treatment, we will examine cell signaling pathways and immune responses in the trial participants which will help us better understand the biology of sarcoidosis and ultimately lead to the development of therapies that target the immune response."
To be eligible for the study, patients must be taking corticosteroids daily for chronic pulmonary sarcoidosis and lung impairment. As many as 90 accepted patients will receive infusion therapy every two weeks for 12 weeks, take CT and PET scans and submit questionnaires. Patients interested in participating in the trial should contact the Clinical Trials Office at 212-241-9538 or visit http://www.mssm.edu/research/resources/office-of-clinical-research.
The Phase I and II clinical trials have been funded by Pfizer.
Jeanne Bernard | EurekAlert!
Mobile phone test can reveal vision problems in time
11.02.2016 | University of Gothenburg
Proteomics and precision medicine
08.02.2016 | University of Iowa Health Care
Today, plants and microorganisms are heavily used for the production of medicinal products. The production of biopharmaceuticals in plants, also referred to as “Molecular Pharming”, represents a continuously growing field of plant biotechnology. Preferred host organisms include yeast and crop plants, such as maize and potato – plants with high demands. With the help of a special algal strain, the research team of Prof. Ralph Bock at the Max Planck Institute of Molecular Plant Physiology in Potsdam strives to develop a more efficient and resource-saving system for the production of medicines and vaccines. They tested its practicality by synthesizing a component of a potential AIDS vaccine.
The use of plants and microorganisms to produce pharmaceuticals is nothing new. In 1982, bacteria were genetically modified to produce human insulin, a drug...
Atomic clock experts from the Physikalisch-Technische Bundesanstalt (PTB) are the first research group in the world to have built an optical single-ion clock which attains an accuracy which had only been predicted theoretically so far. Their optical ytterbium clock achieved a relative systematic measurement uncertainty of 3 E-18. The results have been published in the current issue of the scientific journal "Physical Review Letters".
Atomic clock experts from the Physikalisch-Technische Bundesanstalt (PTB) are the first research group in the world to have built an optical single-ion clock...
The University of Würzburg has two new space projects in the pipeline which are concerned with the observation of planets and autonomous fault correction aboard satellites. The German Federal Ministry of Economic Affairs and Energy funds the projects with around 1.6 million euros.
Detecting tornadoes that sweep across Mars. Discovering meteors that fall to Earth. Investigating strange lightning that flashes from Earth's atmosphere into...
Physicists from Saarland University and the ESPCI in Paris have shown how liquids on solid surfaces can be made to slide over the surface a bit like a bobsleigh on ice. The key is to apply a coating at the boundary between the liquid and the surface that induces the liquid to slip. This results in an increase in the average flow velocity of the liquid and its throughput. This was demonstrated by studying the behaviour of droplets on surfaces with different coatings as they evolved into the equilibrium state. The results could prove useful in optimizing industrial processes, such as the extrusion of plastics.
The study has been published in the respected academic journal PNAS (Proceedings of the National Academy of Sciences of the United States of America).
Exceeding critical temperature limits in the Southern Ocean may cause the collapse of ice sheets and a sharp rise in sea levels
A future warming of the Southern Ocean caused by rising greenhouse gas concentrations in the atmosphere may severely disrupt the stability of the West...
12.02.2016 | Event News
09.02.2016 | Event News
02.02.2016 | Event News
12.02.2016 | Physics and Astronomy
12.02.2016 | Life Sciences
12.02.2016 | Medical Engineering